Skip to main content
Fig. 3 | BMC Cardiovascular Disorders

Fig. 3

From: Allicin protects against LPS-induced cardiomyocyte injury by activating Nrf2-HO-1 and inhibiting NLRP3 pathways

Fig. 3

Allicin activated Nrf2-HO-1 signaling pathway in LPS-induced cardiomyocytes. H9c2 cells were pretreated with 50 µM Allicin, followed by incubation with LPS (10 µg/mL) for 24 h. RT-qPCR showed that Allicin did not change mRNA expression of Nrf2 (A) but enhanced mRNA expression of HO-1 (B) in H9c2 cells with LPS. (C) Representative western blot images investigating Nrf2 and HO-1. Allicin did not change Nrf2 protein (D) but enhanced HO-1 protein (E). (F) Representative western blot images investigating nuclear Nrf2 protein. (G) Quantitative results of western blot analysis on nuclear Nrf2. **P < 0.01 vs. control group; ##P < 0.01, ###P < 0.001 vs. LPS group

Back to article page